Abstract
Background/Objectives:
Quercetin supplementation results in a variable plasma quercetin response in humans. The purpose of this study was to determine whether this variance is related to gender, age, body mass index (BMI), and other demographic and lifestyle factors.
Subjects/Methods:
Subjects (N=1002, ages 18–85 years, 60% female and 40% male) were recruited from the community and randomized to one of three groups, with supplements administered using double-blinded procedures: Q-500 (500 mg/day), Q-1000 (1000 mg/day), or placebo. Subjects ingested two soft chew supplements twice daily during the 12-week study. Fasting blood samples were obtained pre- and post-study, analyzed for plasma quercetin, and then compared between and within groups by gender, age group (<40, 40–59, and ⩾60 years), BMI (<25, 25–29.9, and ⩾30 kg/m2), self-reported physical fitness level, and diet intake (food group servings).
Results:
Quercetin supplementation over 12 weeks caused a significant increase in overnight-fasted plasma quercetin, with a net increase of 332±21.0 and 516±30.8 μg/l for Q-500 and Q-1000 compared with 53.6±6.4 μg/l for placebo (interaction effect, P<0.001). The increase in plasma quercetin was highly variable within each quercetin supplementation group, but was unrelated to age, gender, BMI, fitness levels, or diet intake.
Conclusions:
In summary, quercetin supplementation in doses of 500 and 1000 mg/day caused large but highly variable increases in plasma quercetin that were unrelated to demographic or lifestyle factors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Barnes S (2008). Nutritional genomics, polyphenols, diets, and their impact on dietetics. J Am Diet Assoc 108, 1888–1895.
Boots AW, Haenen GR, Bast A (2008a). Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 585, 325–337.
Boots AW, Wilms LC, Swennen ELR, Kleinjans JCS, Bast A, Haenen G (2008b). In vitro and ex vivo anti-inflammatory activity of quercetin in healthy volunteers. Nutrition 24, 703–710.
Boyle SP, Dobson VL, Duthie SJ, Hinselwood DC, Kyle JAM, Collins AR (2000). Bioavailability and efficiency of rutin as an antioxidant: a human supplementation study. Eur J Clin Nutr 54, 774–782.
Conquer JA, Maiani G, Azzini E, Raguzzini A, Holub BJ (1998). Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. J Nutr 128, 593–597.
Davis JM, Murphy EA, Carmichael MD, Davis B (2009). Quercetin increases brain and muscle mitochondrial biogenesis and exercise tolerance. Am J Physiol Regul Integr Comp Physiol 296, R1071–R1077.
Duarte J, Perez-Palencia R, Vargas F, Ocete MA, Perez-Vizcaino F, Zarzuelo A et al. (2001). Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. Br J Pharmacol 133, 117–124.
Edwards RL, Lyon T, Litwin SE, Rabovsky A, Symons JD, Jalili T (2007). Quercetin reduces blood pressure in hypertensive subjects. J Nutr 137, 2405–2411.
Egert S, Bosy-Westphal A, Seiberl J, Kurbitz C, Settler U, Plachta-Danielzik S et al. (2009). Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br J Nutr 102, 1065–1074.
Egert S, Wolffram S, Bosy-Westphal A, Boesch-Saadatmandi C, Wagner AE, Frank J et al. (2008). Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J Nutr 138, 1615–1621.
Erlund I, Kosonen T, Alfthan G, Maenpaa J, Perttunen K, Kenraali J et al. (2000). Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacoly 56, 545–553.
Goldberg DA, Yan J, Soleas GJ (2003). Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 36, 79–87.
Gulati N, Laudet B, Zohrabian VM, Murali R, Jhanwar-Uniyal M (2006). The antiproliferative effect of quercetin in cancer cells is mediated via inhibition of the PI3K-Akt/PKB pathway. Anticancer Res 26, 1177–1181.
Hanasaki Y, Ogawa S, Fukui S (1994). The correlation between active pxygens scavenging and antioxidative effects of flavonoids. Free Radic Biol Med 16, 845–850.
Hollman PC, de Vries JH, van Leeuwen SD, Mengelers MJ, Katan MB (1995). Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr 62, 1276–1282.
Lee ES, Lee HE, Shin JY, Yoon S, Moon JO (2003). The flavonoid quercetin inhibits dimethylnitrosamine-induced liver damage in rats. J Pharm Pharmacol 55, 1169–1174.
Lee RD, Nieman DC (2010). Nutritional Assessment. (5th edn) St Louis: Mosby.
Loke WM, Proudfoot JM, Stewart S, McKinley AJ, Needs PW, Kroon PA et al. (2008). Metabolic transformation has a profound effect on anti-inflammatory activity of flavonoids such as quercetin: lack of association between antioxidant and lipoxygenase inhibitory activity. Biochem Pharmacol 75, 1045–1053.
Lotito SB, Frei B (2006). Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: cause, consequence, or epiphenomenon? Free Radic Biol Med 41, 1727–1746.
Manach C, Morand C, Crespy V, Demigne C, Texier O, Regerat F et al. (1998). Quercetin is recovered in human plasma as conjugated derivatives which retain antioxidant properties. FEBS Lett 426, 331–336.
Manach C, Williamson G, Morand C, Scalbert A, Remesy C (2005). Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81, 230S–242S.
Nieman DC, Henson DA, Davis JM, Murphy EA, Jenkins DP, Gross SJ et al. (2007a). Quercetin's influence on exercise-induced changes in plasma cytokines and muscle and leukocyte cytokine mRNA. J Appl Physiol 103, 1728–1735.
Nieman DC, Henson DA, Davis M, Dumke CL, Gross SJ, Jenkins DP et al. (2007b). Quercetin ingestion does not alter cytokine changes in athletes competing in the Western States Endurance Run. J Interferon Cytokine Res 27, 1003–1011.
Nieman DC, Henson DA, Gross SJ, Jenkins DP, Davis JM, Murphy EA et al. (2007c). Quercetin reduces illness but not immune perturbations after intensive exercise. Med Sci Sports Exerc 39, 1561–1569.
Nieman DC, Henson DA, Maxwell KR, Williams AS, McAnulty SR, Jin F et al. (2009). Effects of quercetin and EGCG on mitochondrial biogenesis and immunity. Med Sci Sports Exerc 41, 1467–1475.
Read MA (1995). Flavonoids: naturally occurring anti-inflammatory agents. Am J Pathol 147, 235–237.
Acknowledgements
This work is funded by Coca-Cola and Quercegen Pharma.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
DC Nieman holds a position on the science advisory board for Quercegen Pharma. The remaining authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Jin, F., Nieman, D., Shanely, R. et al. The variable plasma quercetin response to 12-week quercetin supplementation in humans. Eur J Clin Nutr 64, 692–697 (2010). https://doi.org/10.1038/ejcn.2010.91
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ejcn.2010.91